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Purpose: To determine the prevalence, clinical characteristics and nature of subfoveal
nodules in Coats’ disease and the associated impact on the long-term visual outcome.
Methods: Consecutive cases of Coats’ disease with foveal exudation were retrospectively
reviewed. The presence of a subfoveal nodule or macular ﬁbrosis was recorded. Clinical
characteristics, retinal imaging, and outcome were analyzed by comparative analysis. The
histopathological description of an enucleated eye with subfoveal nodule was performed.
Results: Among 40 patients presenting unilateral Stage 2B or 3A1 Coats’ disease,
a subfoveal nodule was detected in 21 patients (52.5%). The median follow-up was 4.7
years. Nineteen patients (47.5%) did not present a subfoveal nodule. Three patients
(15.8%) without subfoveal nodule and 21 patients (100%) with subfoveal nodule pro-
gressed to a macular ﬁbrotic scar (P , 0.0001), and the mean time of macular ﬁbrosis
onset was 11.0 ± 2.6 months. Final visual acuity was signiﬁcantly worse in patients who
presented a subfoveal nodule at diagnosis (P = 0.01). Of 18 cases with subfoveal nodule
who underwent ﬂuorescein angiography, retinal–retinal anastomosis and neo-
vascularization were detected in 13 (72.2%) and 2 eyes (11.1%), respectively. Histopath-
ological analysis of a subfoveal nodule revealed an aggregate of proteinaceous material
including ﬁbrin, spindle cells, macrophages, and pigmented cells.
Conclusion: The presence of a subfoveal nodule at presentation is a predictive factor for
macular ﬁbrosis development and worse visual outcome in patients with Coats’ disease.
These observations suggest an updated classiﬁcation introducing two subcategories within
Stage 2B: without subfoveal nodule (Stage 2B1) and with subfoveal nodule (Stage 2B2).
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Coats’ disease is a congenital condition predomi-nantly affecting young male subjects and charac-
terized by unilateral retinal telangiectasia and
exudation.1 Shields et al2 have proposed a classiﬁcation
system aimed at predicting the visual prognosis by strat-
ifying cases according to the presence of foveal exudation
and exudative retinal detachment at presentation. A more
favorable visual prognosis is expected in the absence of
foveal exudates at the initial evaluation, while a thick
foveal exudation usually predicts a worse functional out-
come. In addition, Shields et al have mentioned that poor
vision is particularly expected when this exudation
presents as a ﬁbroglial foveal nodule, yet this observation
was not included in their classiﬁcation system.
The terms “subfoveal nodule,”3 “subretinal mounds,”4
“gray nodule,”2 and “macular ﬁbrosis”5 have been em-
ployed to describe a nodular ﬁbrotic lesion usually asso-
ciated with a vascular component within the fovea or the
posterior pole of patients with Coats’ disease. Notably,
Chang et al6 reported in a histological description of eyes
with Coats’ disease the presence of ﬁbrous nodules in the
macular area with variable calciﬁed content.
The aim of this study is to determine the prevalence
and clinical characteristics of subfoveal nodules
From the Department of Ophthalmology, Jules-Gonin Eye
Hospital, Fondation Asile des Aveugles, University of Lausanne,
Lausanne, Switzerland.
None of the authors has any ﬁnancial/conﬂicting interests to
disclose.
This is an open-access article distributed under the terms of the
Creative Commons Attribution-Non Commercial-No Derivatives
License 4.0 (CCBY-NC-ND), where it is permissible to download
and share the work provided it is properly cited. The work cannot
be changed in any way or used commercially without permission
from the journal.
Reprint requests: Francis L. Munier, MD, Department of
Ophthalmology, Jules-Gonin Eye Hospital, Fondation Asile des
Aveugles, University of Lausanne, Avenue de France 15, Lausanne
1004, Switzerland; e-mail: francis.munier@fa2.ch
1591
in Coats’ disease and the associated impact on the
long-term visual outcome, as well as its histopatho-
logical nature.
Methods
This study was designed in accordance with the
tenets of the Declaration of Helsinki and was approved
by the Ethics Committee of the Swiss Federal Depart-
ment of Health (Authorization CER-VD n° 95/15). Re-
cords of patients diagnosed with Coats’ disease between
August 1989 and June 2015 at Jules-Gonin Eye Hos-
pital were retrospectively reviewed at presentation and
for each subsequent visit. General data included patient
age, sex, laterality of Coats’ disease, and symptoms at
presentation. Visual acuities, slit-lamp observations and
tonometry measures were noted. Fundus examination
data were obtained from drawings and color fundus pho-
tographs with RetCam II (Clarity Medical Systems, Inc,
Pleasanton, CA), Optos 200 Tx (Optos, Dunfermline,
United Kingdom), and Panoret-1000 (CMT Medical
Technologies Inc, Valley Stream, NY). The amount of
peripheral telangiectasia and retinal exudation at presen-
tation was quantiﬁed in terms of clock hours, from 1 to
12. Coats’ disease was classiﬁed according to Shields
et al2 into Stage 1, telangiectasia only; Stage 2, telangi-
ectasia and exudation (2A, extrafoveal exudation; 2B,
foveal exudation); Stage 3, exudative retinal detachment
(3A1, extrafoveal subtotal retinal detachment; 3A2,
foveal subtotal retinal detachment; 3B, total retinal
detachment); Stage 4, total detachment and secondary
glaucoma and Stage 5, advanced end-stage disease.
The presence of a subfoveal nodule or macular
ﬁbrosis was recorded. A subfoveal nodule was deﬁned
on fundus examination as a yellow, exudative, pro-
truding, spheroidal lesion. Nodule size was estimated
in papillary diameter. The lesion was conﬁrmed by B-
scan ultrasonography (OTI SCAN 1000; Ophthalmic
Technologies Inc, ON, Canada) and the height of the
nodule was measured. On fundoscopy, the presence of
an associated vascular component and the presence of
hyperpigmentation were also noted. Macular ﬁbrosis
was deﬁned as a subretinal white-gray scar at the
fovea. Findings from ﬂuorescein angiography (FA) on
RetCam II were recorded. The presence of retinal–
retinal anastomosis and/or neovascularization (retinal
or choroidal) was determined by two different ob-
servers (A.D. and F.M.). Data from spectral-domain
optical coherence tomography (SD-OCT) on Spectra-
lis (Heidelberg Engineering, Heidelberg, Germany)
were also recorded when available. The nodule height
was measured as the axial distance between retinal
pigment epithelium (RPE) and the apex of the nodule
by a single examiner (A.M.a).
Patients presenting without foveal exudation
(stage , 2A) or with foveal exudative retinal detach-
ment (.3A2) at presentation and those with follow-up
,12 months were excluded from the study.
Amblyopia Therapy and Visual Acuity Evaluation
Amblyopia therapy was initiated as needed after full
correction of any refractive error. The patching
regimen was adapted to age and was prescribed part-
time to full-time (up to 10 hours daily) depending on
collaboration and results. Maintenance therapy was
continued after stabilization. Parents were encouraged
to stimulate the child during patching hours, with eye–
hand coordination activities. Visual acuity was as-
sessed at the last control, with a minimum indication
of the presence/absence of light perception, then
recordable measurements using Teller cards for the
youngest children, distance best corrected visual acu-
ity (BCVA) with LH (Lea) symbols from 30 months to
4 years, Snellen “E” chart between 4 years and 5 years,
and numbers or letters from 5 years to 6 years of age.
Statistical Analysis
Comparative analyses were performed between
eyes with or without subfoveal nodule. Baseline
clinical characteristics were compared using Mann–
Whitney test for quantitative variables and Chi-
square or Fisher’s exact test for categorical variables
where appropriate, on GraphPad Prism (version 5.0f;
GraphPad Software, La Jolla, CA). Visual acuity lev-
els were reported in decimal unit and the logarithm of
the minimal angle of resolution (LogMAR) was used
to calculate means. In all statistical comparisons, dif-
ferences with a P value inferior to 0.05 were consid-
ered signiﬁcant.
Pathology
Sections of formalin-ﬁxed enucleated eyes with the
diagnosis of Coats’ disease, archived between August
1989 and June 2015, were retrieved from the histo-
pathological ﬁles of Jules-Gonin Eye Pathology Lab-
oratory. Nine cases were identiﬁed and reviewed for
the presence of subfoveal nodules as well as macular
ﬁbrosis. In all cases, hematoxylin eosin stain was
performed. Martius Scarlett Blue stain was realized
additionally on one eye presenting a subfoveal nod-
ule. Immunohistochemical analyses were performed
in this case with the following antibodies from Dako
(Agilent Technologies Inc, Santa Clara, CA): cytoker-
atins (clone AE1-AE3, dilution 1:200), CD68 (clone
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PGM-1, dilution 1:100), CD31 (clone JC70A,
dilution 1:100).
Results
Records of 101 patients with Coats’ disease were
reviewed. Sixty-one patients were excluded of which
51 cases presented stage #2A or $3A2 and 10 cases
had a follow-up shorter than 12 months. Among the
remaining 40 patients presenting Stage 2B or 3A1, 19
patients (47.5%) did not present with subfoveal nodule
nor developed it during follow-up (Figure 1). A sub-
foveal nodule was detected in 21 patients (52.5%): the
diagnosis was made at presentation in 19 cases, and 2
months later in 2 cases, after regression of initially
extended foveal exudates. The median follow-up was
4.7 years (range, 1–18 years). Figure 1 displays 2
cases, with and without subfoveal nodule. Compara-
tive analyses between patients with and without sub-
foveal nodule are shown in Table 1. There were no
signiﬁcant differences in age, sex, extension of telan-
giectasia or exudation at presentation, or follow-up
duration between groups. The development of macular
ﬁbrosis was signiﬁcantly more frequent in patients
with subfoveal nodule (P , 0.0001). All 21 patients
(100%) with subfoveal nodule and 3 patients (15.8%)
without subfoveal nodule progressed to a macular
ﬁbrotic scar. In cases with and without subfoveal nod-
ule, the mean time from diagnosis to the detection of
macular ﬁbrosis was 11.0 ± 2.6 months and 13.6 ± 9.2
months, respectively. Visual acuity levels at the last
recorded visit were signiﬁcantly worse in patients with
subfoveal nodule (P = 0.01). No patient with subfoveal
nodule and 6 patients without subfoveal nodule (31.6%)
showed ﬁnal visual acuities higher than 20/40. When
analyzing separately ﬁnal visual acuity levels in Stage
2B and Stage 3A1 patients, a signiﬁcant difference
between eyes with and without subfoveal nodules was
found only in Stage 2B patients (P = 0.01). The main
causes of severe visual loss (,20/200) in patients with-
out subfoveal nodule were: macular atrophy in n = 3/3
eyes with Stage 2B and tractional retinal detachment
(n = 2/4), macular ﬁbrosis (n = 1/4) and macular atro-
phy (n = 1/4) in eyes with Stage 3A1.
Clinical and imaging characteristics of patients
with subfoveal nodule are summarized in Table 2.
On fundus examination, a vascular element formed
by a second-to-third-order artery and a second-to-
third-order vein was detected entering the subfoveal
nodule in all cases (Figure 1C). Fluorescein angiog-
raphy was available for 18 patients with subfoveal
nodule, 13 of whom underwent FA at presentation
and 15 at the last visit, after the development of
macular ﬁbrosis. At presentation, FA showed a hypo-
ﬂuorescent area corresponding to the nodule during
the early phase (n = 13/13), which remained hypo-
ﬂuorescent (n = 6/13) or became hyperﬂuorescent
Fig. 1. A and B. Two-year-old
boy presenting with Stage-2B
Coats’ disease. Color fundus
photograph (A) showed a yel-
low lesion suggestive of retinal
exudates, and B-scan ultraso-
nography (B) conﬁrmed the
absence of subretinal nodule. C
and D. Four-year-old boy pre-
senting with Stage-2B Coats’
disease. On color fundus pho-
tograph (A), a yellow, exuda-
tive, protruding, subfoveal
spheroidal lesion was visible
and was associated with two
second-order arteries and
a third-order vein entering the
lesion. B-scan ultrasonography
(B) conﬁrmed the presence of
a subretinal nodule (star).
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with minimal leakage (n = 7/13) during the late
phase (Figure 2). After the development of macular
ﬁbrosis, FA showed in most cases an increasing hyper-
ﬂuorescence with well-delimited borders, correspond-
ing to staining (n = 13/15), or less frequently an
increasing and extending hyperﬂuorescence, corre-
sponding to leakage (n = 2/15) (Figure 2). Of 18 pa-
tients with subfoveal nodule who underwent ﬂuorescein
angiography, retinal–retinal anastomosis was detected
in n = 13 eyes (72.2%) and neovascularization in n = 2
eyes (11.1%) (Figure 3). Spectral-domain optical coher-
ence tomography was performed in 14 patients with
subfoveal nodule at the last visit. Spectral-domain opti-
cal coherence tomography at the level of the ﬁbrotic
nodule showed a hyperreﬂective, sharply demarcated
subfoveal lesion associated with a posterior shadowing
effect. There was a moderate retinal layer disorganiza-
tion and retinal thickening, with abrupt elevation of
retinal layers by the underlying hyperreﬂective nodule
(Figure 4). The mean height of ﬁbrotic nodules
measured on spectral-domain optical coherence
tomography was 0.7 ± 0.3 mm.
Table 1. Comparative Analysis Between Eyes With and Without Subfoveal Nodule Among Patients With Stage 2B or 3A1
Coats’ Disease
Eyes Without Subfoveal Nodule Eyes With Subfoveal Nodule P
Baseline
Number of eyes (%) 19 (47.5) 21 (52.5) —
Sex, male/female 16/3 20/1 0.33*
Mean age, years ± SD 4.8 ± 3.6 4.9 ± 3.5 0.78†
Stage, No. (%)
2B 12 (63.2) 17 (80.9) 0.29*
3A1 7 (36.8) 4 (19.1) —
Retinal exudation, clock hours 4.7 2.9 0.19†
Peripheral telangiectasia, clock hours 6.6 6.4 0.74†
Mean follow-up (median, range), years 4.9 (3.2, 1–12.2) 6.3 (5.4, 1–18.0) 0.40†
Outcome
Final BCVA, No. (%)
,20/200 7 (36.8) 8 (38.1) —
20/200–20/50 5 (26.3) 12 (57.1) 0.01‡
20/40–20/20 6 (31.6) 0 (0) —
NA 1 (5.3) 1 (4.8) —
Final BCVA in Stage 2B patients, No. (%)
,20/200 3 (25) 6 (35.3) —
20/200–20/50 3 (25) 10 (58.8) 0.01‡
20/40–20/20 5 (41.7) 0 (0) —
NA 1 (8.3) 1 (5.9) —
Final BCVA in Stage 3A1 patients, No. (%)
,20/200 4 (57.1) 2 (50) 0.63‡
20/200–20/50 2 (28.6) 2 (50) —
20/40–20/20 1 (14.3) 0 —
NA —
Macular ﬁbrosis, No. (%) 3 (15.8) 21 (100) ,0.0001*
*Fisher’s exact test.
†Mann–Whitney–Wilcoxon nonpaired test.
‡Chi-square test.
VEGF, vascular endothelial growth factor; BCVA, best-corrected visual acuity; SD, standard deviation.
Table 2. Clinical and Imaging Characteristics of Subfoveal Nodules in 21 Patients With Stage 2B or 3A1 Coats’ Disease
Presenting a Subfoveal Nodule
At Presentation After Development of Fibrosis
Size, papillary diameter 1.16 ± 0.4 1.06 ± 0.6
Height on ultrasonography, mm 1.41 ± 1.15 1.01 ± 0.49
Associated parafoveal nodule, No. (%) 3/21 (14.3) 3/21 (14.3)
Vascular element entering in the nodule, No. (%) 21/21 (100) 21/21 (100)
Hyperpigmentation, No. (%) 0/21 (0) 12/21 (57.1)
Retinal–retinal anastomosis on FA, No. (%) 7/13 (53.8) 12/15 (80.0)
Neovascularisation on FA, No (%) 2/13 (15.4) 1/15 (6.7)
FA, ﬂuorescein angiography.
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Pathology
Among 101 patients with Coats’ disease followed at
Jules-Gonin Eye Hospital, 11 eyes underwent enucle-
ation with subsequent pathologic evaluation and diag-
nosis conﬁrmation. Nine procedures were performed
at our institution and the corresponding eyes were
available for analysis. In seven cases, there was a com-
plete exudative retinal detachment with telengiectatic
retinal vessels, retinal gliosis, and partial retinal atro-
phy. Several cases exhibited intraretinal and/or prere-
tinal hemorrhages and retinal hard exudate. Inside
exudates, numerous macrophages and cholesterol
crystals were found. In two cases, a dense subretinal
ﬁbrotic lesion was identiﬁed with ﬁbrous RPE meta-
plasia. The subretinal ﬁbrosis also contained isolated
cords and strands of hyperplastic RPE.
One case with Stage 4 Coats’ disease exhibited a nod-
ule underneath the fovea composed by an aggregate
of proteinaceous material, including ﬁbrin (best high-
lighted with Martius Scarlett Blue Stain) and spindle
cells, as well as macrophages and some pigmented cells.
The nodule dimensions were 288 mm · 358 mm. Immu-
nohistochemistry showed that the spindle cells located at
the periphery of the lesion expressed both low and high
molecular weight cytokeratins consistent with a RPE ori-
gin. The nodule also contained CD163+ macrophages.
There was no vascular component within the nodule and
CD31 expression was not observed (Figure 5).
Discussion
In this retrospective series of 40 patients with Stage
2B or 3A1 Coats’ disease, 52.5% presented a subfoveal
nodule that progressed in all affected cases to macular
ﬁbrosis and was associated with a worse visual out-
come. Among patients presenting subfoveal exudation
Fig. 2. A. Color fundus photograph of a two-year-old boy presenting with Stage-2B Coat’s disease and a subfoveal nodule. B and D. Fluorescein
angiography at presentation showed a hypoﬂuorescent subfoveal lesion during early phase and midphase (B and C), which became hyperﬂuorescent
with minimal leakage during the late phase (D) because of the presence of a retinal–retinal anastomosis (C and D, yellow arrows). Note the peripheral
retinal telangiectasias and nonperfusion areas (C) characteristic of Coats’ disease. E. Color fundus photograph from the same patient acquired 6 months
later after he developed macular ﬁbrosis. F and H. Fluorescein angiography showed an increasing hyperﬂuorescence with well-delimited borders
corresponding to staining. Note the scars resulting from peripheral laser photocoagulation of nonperfused areas (G and H).
Fig. 3. A. Color fundus photograph of a one-year-old boy presenting with Stage-3A1 Coat’s disease and a subfoveal nodule. B. Fluorescein angi-
ography showed a retinal–retinal anastomosis at the level of the subfoveal nodule (dotted-line rectangle). C. Magniﬁcation of the rectangular area (B)
showing the retinal–retinal anastomosis.
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without subfoveal nodule, only 15.8% developed mac-
ular ﬁbrosis, leading to higher ﬁnal visual acuities in
this group.
The classiﬁcation system of Coats’ disease by
Shields et al2 takes into account the presence and loca-
tion of lipid exudates at presentation to stratify the
visual prognosis of the disease. Thus, patients without
foveal exudation (Stage 2A) have better functional
outcome than patients presenting with foveal exuda-
tion at diagnosis (Stage 2B). In this study, we showed
that the presence of a subfoveal nodule is a predictor
of worse visual outcome because of the subsequent
development of macular ﬁbrosis. However, the prog-
nosis value of subfoveal nodules regarding ﬁnal visual
function was only conﬁrmed in Stage 2B patients. The
lack of prognosis value in Stage 3A1 is because of the
possible occurrence of other causes of severe visual
loss during the course of the disease, such as tractional
retinal detachment. On the basis of these observations,
the presence of a subfoveal nodule should be included
in the current classiﬁcation to better detect those pa-
tients at higher risk of macular ﬁbrosis and poor visual
outcome. We suggest to update the classiﬁcation sys-
tem of Coats’ disease by introducing two subcatego-
ries within Stage 2B (Foveal exudation): without
subfoveal nodule (Stage 2B1) and with subfoveal
nodule (Stage 2B2) (Table 3).
The analysis of FA showed that the vascular
elements associated with subfoveal nodules were
composed in a majority of cases of a retinal–retinal
anastomosis and of a neovascular complex in some
cases. Interestingly, although Coats’ disease is mainly
characterized by alterations of the peripheral retinal
vasculature, the observation of retinal–retinal anasto-
mosis in the macular area of these patients conﬁrms
that the disease is related to a wider spectrum of
congenital retinal telangiectasis including Type 1
idiopathic macular telangiectasia, as previously sug-
gested.7–9 Moreover, it was recently shown that Type
1 macular telangiectasia patients harbored abnormal
retinal capillary anastomoses in the perifoveal area.10
However, because there has been no report of
subfoveal nodule in the absence of peripheral telan-
giectasia, it is not possible to conﬁrm that all sub-
foveal nodules arise independently of the peripheral
exudation. Some could be caused by severe
Fig. 4. Spectral-domain optical
coherence tomography horizon-
tal sections in 3 patients with
Coats’ disease and a ﬁbrotic
subfoveal nodule observed 9
(A), 12 (B), and 26 (C) months
after presentation, respectively.
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accumulation or exudation in the macula from the
peripheral vascular anomalies. Jumper et al5 have
described the development of macular ﬁbrosis in 11 of
47 patients (23%) with Coats’ disease and its associ-
ation with intraretinal anastomosis and neo-
vascularization. These authors proposed that macular
ﬁbrosis resulted from a neovascular process in
response to the accumulation of lipid exudates.
Recently, Sigler et al4 reported the presence of retinal
angiomatous proliferation with chorioretinal anasto-
mosis,11,12 using spectral-domain optical coherence
tomography only, in 5 of 21 (24%) patients with
Coats’ disease treated by intravitreal bevacizumab.
The authors hypothesized that Coats’ disease involves
an abortive defect during the angiogenesis of the
retinal midcapillary plexus, and that this aberrant
vascular development in the macula could lead to
Type 3 neovascularization with chorioretinal anasto-
mosis although indocyanine green angiography was
not performed. In the present study, we report the
presence of intraretinal or subretinal neo-
vascularization visible on FA in 27.8% of patients
with a subfoveal nodule. However, the presence of
a choroidal component was not possible to identify
using only spectral-domain optical coherence tomog-
raphy because of the lack of indocyanine green
angiography, not routinely performed in children and
adolescent patients with Coats’ disease. Because
macular ﬁbrosis is the possible result of lipid accu-
mulation from aberrant retinal vessels or neo-
vascularization, treatment by intravitreal anti-vascular
endothelial growth factor (anti-VEGF) agents seems
to be a relevant strategy. However, the possible con-
tribution of anti-VEGF therapy to the development of
ﬁbrosis in Coats’ disease is still controversial.13,14
Whether anti-VEGFs should be systematically indi-
cated when a subfoveal nodule is present remains to
be determined.
In a previous histopathological description of 62
eyes enucleated for severe Coats’ disease, Chang et al6
observed in 6 eyes a subfoveal ﬁbrotic nodule with
RPE proliferation, which occasionally contained
Fig. 5. Histopathological anal-
ysis of a subfoveal nodule from
an eye with Coats’ disease.
Speciﬁc stainings were per-
formed for hematoxylin eosin
(A, ·126), Martius Scarlett Blue
(B, ·126), cytokeratins (AE1–
AE3) (C, ·63), CD68
(D, ·126). The subfoveal lesion
was formed by a round aggre-
gate of proteinaceous material
including ﬁbrin (B) admixed
with spindle cells, macrophages,
and pigmented cells. Some of
the cells within the lesion ex-
pressed pancytokeratins (C)
consistent with a retinal pigment
epithelium origin, while other
expressed CD68 (D). Speciﬁc
staining for endothelial cells
was negative.
Table 3. A Proposed Update for Shields’ Classiﬁcation
System of Coats’ Disease
Stage 1: Telangiectasia only
Stage 2: Telangiectasia and exudation
A: Extrafoveal
B: Foveal
1: Without subfoveal nodule
2: With subfoveal nodule
Stage 3: Exudative retinal detachment
A: Subtotal retinal detachment
1: Extrafoveal
2: Foveal
B: Total retinal detachment
Stage 4: Total detachment and secondary glaucoma
Stage 5: Advanced end-stage disease
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calcium or bone. Our histopathological analysis did
not reveal similar features within subfoveal ﬁbrotic
lesions, but it identiﬁed in one case a nodular aggre-
gate of partially ﬁbrinous material admixed with RPE-
derived cells and macrophages. It is possible that this
aggregate represents an early and incipient phase of
a subsequent subfoveolar ﬁbrosis. We speculate that
the nodule might then adhere to the RPE and to the
sensory retina as local tissue remodeling and ﬁbrosis
progress. We also hypothesize that the composition of
these nodules varies with disease progression, which is
supported by the differential FA behaviors at diagnosis
and after the development of ﬁbrosis, as described in
the present study. At diagnosis, the nodule has most
likely a high lipid content, which is consistent with the
early and late hypoﬂuorescence, in the absence of
leakage from abnormal vessels. With disease progres-
sion, the nodule becomes ﬁbrotic, with frequent hyper-
pigmentation and possible calciﬁcation, modifying its
histological characteristics and increasing its ﬂuores-
cein afﬁnity that manifest as a late staining during FA.
Limitations of this study include its retrospective
nature, the limited number of patients because of the
low prevalence of Coats’ disease, and the absence of
certain imaging modalities in a minority of patients
because of the long inclusion period covering different
eras of modern ocular imaging. Moreover, certain
modalities were not evaluated because they were tech-
nically challenging in young subjects with difﬁculties
to maintain ﬁxation, such as fundus autoﬂuorescence
that could contribute to investigate the possible calci-
ﬁed component of subfoveal nodules. However, the
strong statistical associations reported in the study sup-
port our observations.
In conclusion, the presence of a subfoveal nodule at
presentation is a predictive factor for the development
of macular ﬁbrosis and worse visual outcome in
patients with Coats’ disease and foveal exudation.
Key words: Coats’ disease, subfoveal nodule, mac-
ular ﬁbrosis, outcome, prognosis, retina.
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